SAN DIEGO, July 7, 2015 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at Cantor Fitzgerald's Inaugural Healthcare Conference.
Trovagene is scheduled to present at Cantor Fitzgerald's Inaugural Healthcare Conference at Le Parker Meridien Hotel in New York, NY on July 8, 2015 at 1:30 p.m. EDT. Mr. Schuh will be available for one-on-one meetings during the conference. The presentation will be webcast live at http://wsw.com/webcast/cantor2/trov and can also be accessed through our investor relations page at www.trovagene.com. A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days.
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.
SOURCE Trovagene, Inc.